Clinical Trials Logo

Filter by:
NCT ID: NCT01118325 Completed - Clinical trials for Stable Coronary Artery Disease

An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.

NCT ID: NCT01117987 Terminated - Clinical trials for Pulmonary Arterial Hypertension

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

IMPRES Extn
Start date: April 2010
Phase: Phase 3
Study type: Interventional

This is a multinational, multi center extension study. This study will provide data on the long-term safety, tolerability, and efficacy of imatinib in the treatment of severe pulmonary arterial hypertension.

NCT ID: NCT01116011 Completed - Healthy Clinical Trials

Multiple Ascending Dose Study for AZD 7268 in Japanese Healthy Male Volunteers

JMAD
Start date: April 2010
Phase: Phase 1
Study type: Interventional

This is a multiple ascending dose study (MAD) in the Japanese population with AZD7268. This MAD study will evaluate the safety, tolerability and pharmacokinetics of orally administered AZD7268 after multiple ascending doses.

NCT ID: NCT01115985 Completed - Healthy Clinical Trials

A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This study is to assess the effect of ASP1585 on pharmacokinetics of atorvastatin in 2x2 crossover method.

NCT ID: NCT01115972 Completed - Healthy Clinical Trials

A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This study is to assess the effect of ASP1585 on pharmacokinetics of valsartan in 2x2 crossover method

NCT ID: NCT01115946 Completed - Healthy Clinical Trials

A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Enalapril in Healthy Volunteers

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This study is to assess the effect of ASP1585 on pharmacokinetics of enalapril in 2x2 crossover method.

NCT ID: NCT01115933 Completed - Clinical trials for Coronary Artery Disease

A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population

SV JAPAN
Start date: April 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of the AVJ-09-385 Small Vessel Everolimus Eluting Coronary Stent System (EECSS) (2.25 mm diameter stent) in treatment of subjects with ischemic heart disease caused by de novo lesions.

NCT ID: NCT01115855 Completed - Heart Failure Clinical Trials

Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure

J-EMPHASIS-HF
Start date: July 2010
Phase: Phase 3
Study type: Interventional

A study to compare the efficacy and safety of eplerenone in Japanese chronic heart failure patients with placebo.

NCT ID: NCT01114828 Completed - Cirrhosis Clinical Trials

A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema

Start date: February 2010
Phase: Phase 3
Study type: Interventional

OPC-41061 at 3.75 mg/day or 7.5 mg/day will be orally administered once daily for 7 days to cirrhosis patients with ascites despite having received treatment with conventional diuretics and pharmacodynamics, pharmacokinetics, efficacy, and safety will be investigated.

NCT ID: NCT01114620 Completed - Influenza Clinical Trials

Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older

Start date: May 17, 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to comply with the post marketing condition to the exceptional approval of Arepanrix™ in Japan and to assess the immunogenicity and safety of GSK Biologicals' H1N1 influenza vaccine healthy Japanese adults 65 years of age or older.